GHK-Cu vs Melanotan I
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Copper Peptide, Glycyl-L-histidyl-L-lysine copper
A naturally occurring copper-binding peptide found in human plasma, saliva, and urine. Widely used in skincare for its wound healing and anti-aging properties.
Also: Afamelanotide, Scenesse
A 13-amino acid synthetic analog of α-MSH that stimulates melanin production. FDA-approved (as Scenesse) for treating phototoxicity in patients with erythropoietic protoporphyria (EPP). More selective than Melanotan II with fewer side effects.
Key Comparison Insights
- Melanotan I is FDA approved, while GHK-Cu remains in research stages.
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- Melanotan I has stronger research evidence (FDA Approved) compared to GHK-Cu (Human Trials).
Detailed Comparison
| Attribute | GHK-Cu | Melanotan I |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | GHK-Cu stimulates collagen and elastin synthesis, promotes glycosaminoglycan production, supports blood vessel growth, and has antioxidant and anti-inflammatory properties. It remodels damaged tissue and activates wound-healing genes. | Melanotan I binds to melanocortin 1 receptors (MC1R) on melanocytes, stimulating eumelanin production. This increases skin pigmentation and provides photoprotection. Unlike MT-II, it has minimal affinity for MC3R and MC4R, resulting in fewer sexual and appetite-related side effects. |
| Common Dosing | 1-2 mg daily (injection) or 0.05% topical Once daily | 500-1000 mcg daily (loading), then 500-1000 mcg 1-2x weekly (maintenance) Daily during loading (1-2 weeks), then 1-2x weekly maintenance |
| Administration | Subcutaneous injection or topical application | Subcutaneous implant (not injection) |
| Typical Duration | Varies by application | Long-term / as needed before sun season |
| Best Time to Take | Evening (for skin/recovery) | Evening or before sun exposure |
Possible Side Effects May vary by individual |
|
|
| Research Summary | 2023 double-blind split-face study (n=60) showed 22% increased skin firmness and 16% reduction in fine lines with 0.05% GHK-Cu serum. 2024 multicenter study found 25% faster epithelial recovery after laser resurfacing. 2025 research demonstrated anti-inflammatory effects in ulcerative colitis model via SIRT1/STAT3 pathway. Growing evidence for wound healing and anti-aging applications. | FDA approved in 2019 for EPP after successful Phase III trials showing significant increase in pain-free time in sunlight. Also studied for vitiligo, polymorphous light eruption, and solar urticaria. Clinuvel Pharmaceuticals developed and markets it as Scenesse. |
Frequently Asked Questions: GHK-Cu vs Melanotan I
What is the difference between GHK-Cu and Melanotan I?
GHK-Cu is a skin & hair peptide that a naturally occurring copper-binding peptide found in human plasma, saliva, and urine. widely used in skincare for its wound healing and anti-aging properties. Melanotan I is a skin & hair peptide that a 13-amino acid synthetic analog of α-msh that stimulates melanin production. fda-approved (as scenesse) for treating phototoxicity in patients with erythropoietic protoporphyria (epp). more selective than melanotan ii with fewer side effects. The main differences lie in their mechanisms of action and clinical applications.
Which is better, GHK-Cu or Melanotan I?
Neither is universally "better" - the choice depends on your specific goals. GHK-Cu is typically used for skin & hair purposes, while Melanotan I is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can GHK-Cu and Melanotan I be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using GHK-Cu and Melanotan I together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.